HC Wainwright reiterated their buy rating on shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in a report issued on Friday. They currently have a $7.00 price target on the biotechnology company’s stock.
Several other analysts have also recently commented on the company. Maxim Group restated a buy rating and issued a $5.00 price target on shares of Viking Therapeutics in a report on Wednesday, October 4th. ValuEngine cut Viking Therapeutics from a sell rating to a strong sell rating in a report on Friday, July 28th.
Viking Therapeutics (NASDAQ:VKTX) traded up $0.55 on Friday, reaching $2.74. The company’s stock had a trading volume of 1,277,700 shares, compared to its average volume of 312,075. Viking Therapeutics has a 52 week low of $0.88 and a 52 week high of $3.24.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). equities research analysts forecast that Viking Therapeutics will post -0.81 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/11/11/viking-therapeutics-inc-vktx-given-buy-rating-at-hc-wainwright.html.
Several large investors have recently modified their holdings of VKTX. Citadel Advisors LLC purchased a new stake in shares of Viking Therapeutics during the 3rd quarter worth about $108,000. Virtu KCG Holdings LLC purchased a new stake in shares of Viking Therapeutics during the 2nd quarter worth about $124,000. Renaissance Technologies LLC grew its holdings in shares of Viking Therapeutics by 62.9% during the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 102,600 shares during the period. Sabby Management LLC purchased a new stake in shares of Viking Therapeutics during the 2nd quarter worth about $525,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Viking Therapeutics during the 3rd quarter worth about $554,000. Institutional investors and hedge funds own 5.54% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.